Benzinga | Dec 4, 2020 05:20AM EST

Mizuho Upgrades Sage Therapeutics to Buy, Raises Price Target to $81

Mizuho upgrades Sage Therapeutics (NASDAQ:SAGE) from Neutral to Buy and raises the price target from $77 to $81.